BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Anika Therapeutics 

32 Wiggins Avenue

Bedford  Massachusetts  01730   U.S.A.
Phone: 781-457-9000 Fax: 781-935-4120


View Clinical Trials from BioPharm Insight

Anika Therapeutics is a pioneer in developing therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring polymer found throughout the body. HA enhances joint function and coats, protects, cushions and lubricates soft tissues. HA also is present in the skin, where it supports skin structure and elasticity. With more than 20 years of experience in HA technology, Anika is recognized worldwide as a provider of premium HA products that are effective, safe and long-lasting.

Anika manufactures and distributes a diverse portfolio of HA-based products that cover a broad range of therapeutic applications. These products include ORTHOVISC®, ORTHOVISC® mini, and MONOVISC™ used in the treatment of osteoarthritis; HYVISC® used in the treatment of equine osteoarthritis; the ELEVESS™ family of cosmetic dermatology products for facial wrinkles, scar remediation and lip augmentation; AMVISC®, AMVISC® Plus, STAARVISC™ II, and OPTIVISC™ injectable viscoelastic HA products for ophthalmic surgery; INCERT®, an HA-based anti-adhesive for surgical applications; and next-generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA.

 Key Statistics

Ownership: Public

Web Site: Anika Therapeutics
Symbol: ANIK


 Company News
Anika Therapeutics (ANIK) To Present At Jefferies and Co. 2015 Global Healthcare Conference On June 4 5/22/2015 6:35:15 AM
Anika Therapeutics (ANIK) Announces Presentation Of Seven Abstracts At 12th Annual World Congress Of The International Cartilage Repair Society 4/29/2015 12:14:28 PM
Anika Therapeutics (ANIK) Reports First-Quarter 2015 Financial Results 4/29/2015 12:12:20 PM
Anika Therapeutics (ANIK)' Cingal 13-02 Study Meets Primary Endpoint 4/20/2015 6:42:43 AM
Anika Therapeutics (ANIK) Reports On Cingal 13-01 Study Clinical Trial Top Line Data And Announces The Completion Of Cingal 13-02 Study’s Patient Enrollment 4/17/2015 8:56:29 AM
Anika Therapeutics (ANIK) Announces Date Of First-Quarter 2015 Financial Results Conference Call 4/16/2015 12:31:03 PM
Anika Therapeutics (ANIK) Release: Hyalomatrix Receives CMS Reimbursement Coverage In 11 States 4/13/2015 11:36:41 AM
Anika Therapeutics (ANIK) Files IDE Application With U.S. FDA For Hyalofast 4/9/2015 9:25:33 AM
Anika Therapeutics (ANIK) To Present At Canaccord Genuity Musculoskeletal Conference March 24 3/18/2015 9:53:17 AM
Anika Therapeutics (ANIK) Reports Fourth-Quarter And Full-Year 2014 Financial Results 2/26/2015 11:38:37 AM